Literature DB >> 27776398

The Relief Effects of Ramelteon on Refractory Chronic Migraine: A Case Report.

Yi-Cheng Hou1, Chien-Han Lai2,3.   

Abstract

The selective melatonin receptor agonism effect of ramelteon is useful for insomnia. Here we wanted to present a refractory chronic migraine case, who had significant improvements in migraine after using ramelteon. The possible mechanism for the ramelteon in the migraine relief might be related to melatonin effects.

Entities:  

Keywords:  Migraine disorders; Ramelteon; Sleep wake disorders

Year:  2016        PMID: 27776398      PMCID: PMC5083936          DOI: 10.9758/cpn.2016.14.4.405

Source DB:  PubMed          Journal:  Clin Psychopharmacol Neurosci        ISSN: 1738-1088            Impact factor:   2.582


INTRODUCTION

The selective melatonin receptor agonism effect of ramelteon is useful for insomnia.1) Here we wanted to present a refractory chronic migraine case, who had significant improvements in migraine after using ramelteon.

CASE

A 71 years old female patient suffered from chronic migraine for 2 decades. She never had insomnia problems before the first onset of migraine. The migraine occurred 3–4 times per week and each episode persisted around 4–8 hours. The pulsating pain was localized at right half of the head. The precipitating factors were the stress, increase in physical activities and sudden cold weather. The relieving factors included warm temperature, slower pacing of life and comfortable environment. The moderate or severe pain intensity was aggravated by or causing avoidance of increased physical activity. The residual symptom between the migraine episodes were the head tense feeling, but not achieveing headache severity. The function remained well except avoiding exercise between migraine episodes. No family history of headache was mentioned. The diagnosis was made by the International Headache Society criteria for migraine. The computed tomography revealed no significant findings of other causes for headache, such as tumor or hemorrhage. She ever received many kinds of medications, such as aspirin, nonsteroidal anti-inflammatory drugs, triptans, ergots, anticonvulsants and glucocorticoids. However, the severity of migraine still remained moderate (Migraine Disability Assessment Test [MIDAS] scores, 19) and the associated symptoms were moderate headache, dizziness, nausea, and sensitivity to sound. The migraine also exacerbated her insomnia problems, with fragmented sleep and inadequate sleep duration as 1–2 hours (Insomnia Severity Index [ISI] score, 23). She didn’t have any comorbid mental disorder except insomnia. Due to the fear of abuse potential related to hypnotics, she chose to receive ramelteon to relieve insomnia. The concurrent analgesic medicine for migraine was ibuprofen 400 mg/day. After 2 weeks treatment of ramelteon 8 mg/day, her sleep duration prolonged to 4–5 hours with less fragmentation. In addition, her migraine severity started to decline (MIDAS scores, 11). After 6 months of ramelteon 8 mg/day treatment, the migraine severity continued to relieve (MIDAS scores, 6) with stable sleeping quality (ISI score, 14).

DISCUSSION

In this case, we found significant improvements in migraine severity and insomnia after the use of ramelteon. Since the patient didn’t have insomnia before the first onset of migraine. Therefore we could speculate that the ramelteon had significant effects in migraine in such mild prolongation of sleep duration. The melatonin might relieve the headache via the following possible mechanisms, such as anti-inflammatory effect, free radical scavenging, reduction of pro-inflammatory cytokine, membrane stabilization, nitric oxide synthase activity and dopamine release inhibition, GABA and opioid analgesia potentitation, glutamate neurotoxicity protection, neurovascular regulation,2) cytoprotection and antiallodynic action.3) The pineal gland, the primary source of serotonin and melatonin, might also play a significant role in the analgesic effect.4) However, the clinical trial of melatonin administration showed no significant improvements in migraine severity,5) which suggested the modulation of melatonin receptor might be a better option for the analgesic effects. The modulation of serotonin system by the ramelteon would also relieve the pain sensation.2) In addition, the chemical structure of ramelteon was similar with that of indomethacin, which is a kind of non-steroidal anti-inflammatory medicine.2) In the study of animal model, the antinociceptive and antiallodynic actions of melatonin have been observed in different kinds of pathways, such as intrathecally or intracerebroventricular routes. The use of ramelteon, a kind of MT1 and MT2 agonist, could also relieve the pain even lack of free radical scavenger effects.3) The state-of-art treatment of refractory chronic migraine also includes the ramelteon due to selective M1 receptor agonism.6) From the successful experience in this case, we can consider the use of ramelteon for refractory chronic migraine with insomnia.
  6 in total

1.  Prophylaxis of migraine with melatonin: a randomized controlled trial.

Authors:  Karl B Alstadhaug; Francis Odeh; Rolf Salvesen; Svein I Bekkelund
Journal:  Neurology       Date:  2010-10-26       Impact factor: 9.910

Review 2.  Emerging treatment for chronic migraine and refractory chronic migraine.

Authors:  Luana Lionetto; Andrea Negro; Stefano Palmisani; Giovanna Gentile; Maria Rosaria Del Fiore; Marco Mercieri; Maurizio Simmaco; Thomas Smith; Adnan Al-Kaisy; Roberto Arcioni; Paolo Martelletti
Journal:  Expert Opin Emerg Drugs       Date:  2012-08-03       Impact factor: 4.191

3.  Melatonin: a significant contributor to the pathogenesis of migraine.

Authors:  J U Toglia
Journal:  Med Hypotheses       Date:  2001-10       Impact factor: 1.538

Review 4.  Potential use of melatonergic drugs in analgesia: mechanisms of action.

Authors:  Venkataramanujam Srinivasan; Seithikurippu R Pandi-Perumal; D Warren Spence; Adam Moscovitch; Ilya Trakht; Gregory M Brown; Daniel P Cardinali
Journal:  Brain Res Bull       Date:  2010-01-19       Impact factor: 4.077

Review 5.  Potential therapeutic use of melatonin in migraine and other headache disorders.

Authors:  Mario F P Peres; Marcelo R Masruha; Eliova Zukerman; Carlos Alberto Moreira-Filho; Esper A Cavalheiro
Journal:  Expert Opin Investig Drugs       Date:  2006-04       Impact factor: 6.206

Review 6.  Ramelteon: a novel approach in the treatment of insomnia.

Authors:  Jill N Reynoldson; Ellie Elliott; Leigh Anne Nelson
Journal:  Ann Pharmacother       Date:  2008-07-23       Impact factor: 3.154

  6 in total
  1 in total

Review 1.  The Pathogenetic Role of Melatonin in Migraine and Its Theoretic Implications for Pharmacotherapy: A Brief Overview of the Research.

Authors:  Anna Zduńska; Joanna Cegielska; Izabela Domitrz
Journal:  Nutrients       Date:  2022-08-15       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.